Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease
about
The promise of neuroprotective agents in Parkinson's diseaseAnti-inflammatory drugs and risk of Parkinson disease: A meta-analysisNon-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson's disease: evidence from observational studiesNon-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson's disease: evidence from observational studiesUse of ibuprofen and risk of Parkinson diseaseNeuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent PerspectivesNeuroinflammation in the pathophysiology of Parkinson's disease and therapeutic evidence of anti-inflammatory drugsEffect of non-steroidal anti-inflammatory medications on the risk of amyotrophic lateral sclerosisMicroglia-mediated neurotoxicity: uncovering the molecular mechanismsParkinson's disease or Parkinson symptoms following seasonal influenza.Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic interventionCyclooxygenase and neuroinflammation in Parkinson's disease neurodegeneration.Risk for Parkinson's disease among patients with osteoarthritis: a Danish cohort study.Microglial phenotype and adaptation.Use of non-steroidal anti-inflammatory drugs and risk of Parkinson's disease: nested case-control study.Non-steroidal anti-inflammatory drug use and the risk of Parkinson's disease.Attenuation of inflammatory-mediated neurotoxicity by Saururus chinensis extract in LPS-induced BV-2 microglia cells via regulation of NF-κB signaling and anti-oxidant properties.Temporal mRNA profiles of inflammatory mediators in the murine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine model of Parkinson's diseaseThe distinct roles of cyclooxygenase-1 and -2 in neuroinflammation: implications for translational research.Modulation of microglial pro-inflammatory and neurotoxic activity for the treatment of Parkinson's disease.Diabetes in patients with idiopathic Parkinson's disease.Death in the substantia nigra: a motor tragedy.Inflammation and clinical presentation in neurodegenerative disease: a volatile relationship.Parkinson's disease and enhanced inflammatory response.Neuroinflammation in Parkinson's disease.Use of antidepressants and the risk of Parkinson's disease: a prospective study.Targets for neuroprotection in Parkinson's diseaseMicroglial responses to dopamine in a cell culture model of Parkinson's disease.Innate and adaptive immunity for the pathobiology of Parkinson's diseaseAutoimmune disease and risk for Parkinson disease: a population-based case-control study.Pathogenesis-targeted, disease-modifying therapies in Parkinson disease.Peripheral inflammation increases the damage in animal models of nigrostriatal dopaminergic neurodegeneration: possible implication in Parkinson's disease incidence.Parkinson's disease: evidence for environmental risk factors.Neuroinflammation in Parkinson's disease: role in neurodegeneration and tissue repair.How can we address the controversies surrounding the use of NSAIDS in neurodegeneration?The role of the MYD88-dependent pathway in MPTP-induced brain dopaminergic degenerationAnti-inflammatory and neuroprotective activity of boswellic acids in rotenone parkinsonian rats.Non-Steroidal Anti-Inflammatory Drugs in Alzheimer's Disease and Parkinson's Disease: Reconsidering the Role of Neuroinflammation.Cyclooxygenase-2 contributes to oxidopamine-mediated neuronal inflammation and injury via the prostaglandin E2 receptor EP2 subtype.Inflammatory mechanisms of neurodegeneration in toxin-based models of Parkinson's disease.
P2860
Q21129436-5D8CEEA0-BA6B-420B-806F-E1E9212757AAQ22241651-72EE5E17-0C33-43CE-BB4E-AFE886D9981DQ24235107-602B9D21-2C98-4DB7-8165-DD618767CAFEQ24236199-C4E3B51F-5242-4296-B4D2-2DDD7A5854C6Q24594751-40508A66-8204-4154-B0F1-8D5F5953383FQ26747508-B9FD390D-EBA9-43C8-AB7C-653AE243FD0DQ26801035-9F45C182-D707-429E-B597-A6D047527C4AQ28211897-20AA5B23-36E5-4515-A43A-2A7EDA048EFBQ29547835-7A1B9F58-DE68-4C4D-8E3C-B439FB94220AQ30403795-2CC9DB27-1DBC-4163-8881-6F547E0C7F52Q33663970-B44D0E14-57AC-4403-9D9A-DF07D77FEB7AQ33836942-8EC6F414-5669-434F-B995-B0259A5E2228Q34353167-6B41C2B4-4FB2-419C-BD06-B35B479B5E0EQ34359569-98DDC953-A4FB-44DE-AEB2-10CC223DF3E8Q34505182-909E151D-E706-4029-909D-A982FE89E75EQ34985170-20321980-D400-4A91-9A6C-62DFB702A767Q34994982-7FCBB415-83C3-4F37-954C-89625A3BBC49Q35846770-77915837-8069-4917-875C-959763C6417AQ36048230-489FECFF-B9EC-436F-8BD2-53137BCA9CE3Q36616362-66D2B4AA-9A5D-4917-B8E2-89A6A5CCBE08Q36842047-5DD89D40-BAB9-46EE-BAC8-DEA350C04D05Q36847262-61FDC3CC-007B-4085-BD7A-4DECC4DDEE55Q37069901-4C150A42-B44D-445B-87A8-AB9ABE4C3B4DQ37071201-CE548449-7619-4ED3-9F74-C9277E7E107CQ37079115-ED58C054-329D-4441-9125-DD3AB290F4D9Q37240629-5287D556-3AE8-4789-9D3F-1A51D97C7D23Q37302453-A93DC0E9-9593-4AE6-9F00-588FE4F389ADQ37389383-3B1A77F0-9A3A-4D45-BE89-C5403CFB4CA0Q37401280-0B17C611-E2F4-40F0-BD8F-C9D352BFF2F2Q37425099-B92B35B8-8F62-4BCD-9C79-0D97FA8C870EQ37506492-D918CE94-B2F6-4FAC-9C9F-85F3F7522188Q37878282-A597B779-583F-4287-B0E5-EEAB47E9D8F3Q38055457-0CB3DC1D-EAA9-4BD6-8A08-0F09148B627CQ38264485-0FDE506A-B782-4A7F-9032-BC73038C4161Q38846986-BDAFCCBC-2BED-4A6B-BC9B-771F7F1E1FC3Q38860761-635EB599-34B7-465F-8D81-FB688BB355F3Q38935503-569373C4-E6AE-4E7F-8BB0-3C3E30C40A66Q38974344-304672A0-3B99-42CB-BF26-4D0B25999953Q41533962-AAA75C0C-460E-4EBB-8870-FD93E0537C80Q41917715-ABF7413A-452C-4A3C-B1D2-632C0FC85F2A
P2860
Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease
description
2006 nî lūn-bûn
@nan
2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease
@ast
Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease
@en
Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease
@nl
type
label
Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease
@ast
Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease
@en
Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease
@nl
prefLabel
Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease
@ast
Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease
@en
Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease
@nl
P3181
P1433
P1476
Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease
@en
P2093
Luis A García Rodríguez
Miguel A Hernán
P304
P3181
P356
10.1212/01.WNL.0000204446.82823.28
P407
P577
2006-04-11T00:00:00Z